OrigiMed

Core Business Focus

OrigiMed's central mission is to advance precision oncology in China by making comprehensive tumor genomic testing accessible and clinically meaningful. Cancer is fundamentally a disease of the genome, and identifying the specific molecular alterations driving an individual patient's tumor can determine whether targeted drugs or immunotherapies are likely to be effective. OrigiMed provides the testing and analytical infrastructure needed to identify these alterations and match patients with appropriate therapies, including approved drugs, clinical trial opportunities, and off-label options supported by evidence.

The company serves two primary constituencies:

• Clinical oncologists and cancer patients who need genomic information to inform individualized treatment plans.
• Biopharmaceutical and biotechnology companies that require genomic testing services, biomarker development, and real-world data to support drug development, clinical trials, and companion diagnostic programs.

Products and Services

Comprehensive Genomic Profiling

OrigiMed's flagship offerings are comprehensive genomic profiling (CGP) tests that analyze hundreds of cancer-related genes in a single assay. These panels detect the major classes of genomic alterations relevant to cancer treatment, including single nucleotide variants, insertions and deletions, copy number variations, and gene fusions or rearrangements. By examining a broad set of genes simultaneously, CGP maximizes the chance of finding clinically actionable targets from a single tissue or blood sample.

Immunotherapy Biomarker Testing

Recognizing the growing importance of immuno-oncology, OrigiMed provides testing for biomarkers that predict response to immune checkpoint inhibitors. These include tumor mutational burden (TMB) and microsatellite instability (MSI), both of which are established indicators used to identify patients who may benefit from immunotherapy drugs such as PD-1 and PD-L1 inhibitors.

Solid Tumor and Hematologic Panels

The company offers a range of testing products tailored to different cancer types and clinical needs. These include broad pan-cancer panels covering solid tumors as well as more focused panels designed for specific tumor types or specific clinical questions. Testing can be performed on tumor tissue samples as well as through liquid biopsy approaches that analyze circulating tumor DNA (ctDNA) from blood, which is particularly valuable when tissue samples are limited or when monitoring disease over time.

Clinical Interpretation and Reporting

A key part of OrigiMed's value proposition is not simply generating sequencing data but interpreting it. The company produces clinical reports that translate raw genomic findings into treatment-relevant information. These reports connect detected alterations to relevant targeted therapies, immunotherapy indications, resistance mechanisms, and applicable clinical trials, drawing on a curated knowledge base of oncology evidence and drug information.

Pharmaceutical and Biotech Partnership Services

Beyond direct clinical testing, OrigiMed provides services to the pharmaceutical industry. These include biomarker discovery and validation, companion diagnostic development, patient stratification and enrollment support for clinical trials, and access to genomic and real-world clinical data. Through these collaborations, OrigiMed supports drug developers in designing more efficient trials and in bringing targeted and immuno-oncology therapies to market in China and globally.

Genomic Data and Real-World Evidence

OrigiMed has accumulated a substantial database of Chinese cancer patient genomic and clinical data. This dataset is valuable for understanding the molecular epidemiology of cancer in the Chinese population, which can differ from Western populations in the frequency of certain mutations. The company leverages this data resource to support research, publications, and pharmaceutical partnerships focused on the Chinese and Asian cancer landscape.

Technology and Laboratory Capabilities

OrigiMed operates its own clinical laboratory and applies next-generation sequencing platforms combined with proprietary bioinformatics pipelines to process samples at scale. The company emphasizes analytical rigor, quality control, and clinical-grade standards in its testing workflow. Its bioinformatics and knowledge base systems are designed to keep pace with the rapidly evolving body of oncology evidence, ensuring that reports reflect current therapies and research findings.

The company has pursued recognized quality standards and has been involved in efforts to align its testing with regulatory and industry benchmarks, reflecting the broader maturation of China's molecular diagnostics industry.

Market Position and Significance

OrigiMed is regarded as one of the notable players in China's precision oncology and cancer genomics field, alongside a competitive landscape of domestic diagnostics companies. The company has attracted significant venture and strategic investment to support its growth, reflecting investor confidence in the expansion of precision medicine within China. China represents one of the world's largest cancer patient populations, creating substantial demand for genomic testing and targeted therapy guidance, and OrigiMed's offerings are aimed directly at meeting this need.

By combining clinical testing, data analytics, and pharmaceutical collaboration, OrigiMed contributes to the broader ecosystem that connects cancer patients with personalized treatment options and helps advance the development of new cancer drugs in the Chinese market.

Summary

OrigiMed is a Shanghai-based precision oncology and cancer genomics company that delivers comprehensive genomic profiling, immunotherapy biomarker testing, and molecular diagnostics to guide personalized cancer care. Serving both clinicians and the biopharmaceutical industry, the company pairs next-generation sequencing and advanced bioinformatics with clinical interpretation, real-world data, and partnership services. Through these capabilities, OrigiMed supports the matching of cancer patients to targeted and immunotherapy treatments and plays a role in advancing drug development within China's growing precision medicine sector.